PRx is distinguished by its seasoned management team that has amassed more than 65 years of experience in the biotechnology and device industries including founding and securing funding for several early stage companies. Specific skill sets include product development, clinical trials management, operations, manufacturing, finance, regulatory, and all aspects of polymer technology specific to the Company’s IP portfolio.
James T. Posillico, Ph.D.
Chairman & CEO
James T. Posillico, Ph.D. earned his doctorate degree in endocrinology and cell biology at Duke University and completed a post-doctoral fellowship at Harvard Medical School (HMS). He continued his academic career in the field of endocrinology and metabolism as Assistant Professor of HMS. Dr. Posillico joined the Ares-Serono Group, a Swiss-based biotechnology company, and became Vice President of Scientific and Medical Affairs for the Division of International Business Operations for. In this capacity, he was primarily responsible for establishing new operating subsidiaries in international markets that included managing the Division's regulatory and clinical development programs as well as its business development initiatives. During his tenure at Serono, he played key executive leadership roles in strategic planning, business transactions, corporate partnerships and the successful regulatory approval of several pharmaceutical products.
Dr. Posillico left Ares-Serono to become President and CEO of the Canadian biotechnology company, InterMune Life Sciences and subsequently founded and served as CEO of SAGE BioPharma; both companies developed therapeutic products and medical devices for the field of assisted reproductive medicine. With the acquisition of SAGE BioPharma by Cooper Surgical Inc., Dr. Posillico became that company's Chief Scientific Officer and VP of Strategic Development. Posillico later founded and served as CEO of the metabolomics company, Molecular Biometrics, LLC, to develop advanced diagnostic products for the infertility market. In the course of his career, Dr. Posillico raised significant capital from numerous sources to fund operations of his business ventures. In his academic and corporate careers, Dr. Posillico received several awards for teaching and for his business accomplishments. He is a co-founder and currently serves as Chairman and CEO of Polymer Therapeutics, LLC, a medical polymer and drug delivery company. Dr. Posillico has over 28 years of health care experience as both an entrepreneur and an industry executive.
Ronald N. DeMartino, Ph.D.
Chief Scientific Officer
Dr. DeMartino has over 30 years experience in industrial polymer research, development and commercialization, primarily at Hoechst-Celanese Corporation, where he was a Senior Research Chemist, Research Supervisor and Project Manager. Dr. DeMartino has extensive experience in polymer synthesis, fabrication and market application, including research and development of a number of diverse polymer systems (natural and synthetic). He has directed multi-disciplinary research and development teams to create new applications/business opportunities with particular emphasis on optimizing polymer properties to match a specific application. He was, in part, responsible for the development and commercialization of a polyester textile fiber that matched the comfort qualities of cotton. Dr. DeMartino holds a Bachelor of Science degree in chemistry from Fairleigh Dickinson University and a doctorate degree in organic chemistry from Fordham University.